AACR: ICMgp100 tolerated, active in advanced melanoma

April 9, 2014
AACR: ICMgp100 tolerated, active in advanced melanoma

(HealthDay)—An affinity-enhanced T cell receptor specific for the human leukocyte antigen-A2 restricted melanoma gp 100 peptide fused to an anti-CD3 antibody fragment, IMCgp100, seems promising for advanced melanoma, according to a study presented at the annual meeting of the American Association for Cancer Research, held from April 5 to 9 in San Diego.

Mark Middleton, M.D., Ph.D., from the NIHR Biomedical Research Centre in Oxford, U.K., and colleagues conducted a phase I study to determine the maximum tolerated dose and toxicity of ICMgp100. Thirty-one patients with were enrolled in eight cohorts and received doses of 5 to 900 ng/kg ICMgp100.

The researchers found that two of four patients developed grade 3 hypotension at a dose of 900 ng/kg, and consequently the maximum tolerated dose was established as 600 ng/kg. Transient grade 3 pruritic rash and grade 2 pyrexia were common toxicities. There was evidence of profound lymphocyte trafficking to the skin, as observed in immunohistochemical analysis of skin biopsies, and this was accompanied by chemokine/cytokine release. To date, four partial responses and multiple lesser responses have been documented, with one of the partial responses occurring after a single dose. Two partial responses persisted beyond more than nine months of continued treatment.

"The drug is well tolerated in advanced , and we have seen clinical responses in some of them," Middleton said in a statement.

The study was funded by Immunocore.

Explore further: New antibody-drug conjugate shows early promise against all forms of melanoma

More information: Press Release
More Information

Related Stories

New antibody-drug conjugate shows early promise against all forms of melanoma

April 8, 2014
The investigational drug DEDN6526A, which is a new member of a class of drugs called antibody-drug conjugates, was safe, tolerable, and showed hints of activity against different forms of melanoma—cutaneous, mucosal, and ...

Experimental drug shows early promise for some cases of advanced melanoma

April 8, 2014
(HealthDay)—An experimental cancer drug that activates the immune system has shown early promise for advanced cases of melanoma skin cancer, researchers report.

Chemo combination promising for multiple myeloma

May 2, 2012
(HealthDay) -- For patients with relapsed or refractory multiple myeloma, combination treatment with elotuzumab, lenalidomide, and low-dose dexamethasone is generally well tolerated, with encouraging response rates, according ...

Antibody could be used to target tumor-causing protein, study shows

March 11, 2014
Cincinnati Cancer Center (CCC) and University of Cincinnati (UC) Cancer Institute researchers have found in a phase-1 study that patients with advanced melanoma and kidney cancer who were treated with a certain antibody that ...

AACR: LY2835219 promising for metastatic breast cancer

April 7, 2014
(HealthDay)—The novel cell cycle inhibitor selective for the cyclin-dependent kinases CDK4 and CDK6 (CDK4/6), LY2835219, shows promise for metastatic breast cancer, according to a study presented at the annual meeting of ...

ASCO: Dabrafenib/Trametinib active in metastatic melanoma

May 17, 2012
(HealthDay) -- For patients with V600 BRAF-mutant solid tumors, treatment with the oral BRAF inhibitor dabrafenib and the oral MEK 1/2 inhibitor trametinib is tolerated and has clinical activity in BRAF inhibitor-naive metastatic ...

Recommended for you

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

These foods may up your odds for colon cancer

January 18, 2018
(HealthDay)—Chowing down on red meat, white bread and sugar-laden drinks might increase your long-term risk of colon cancer, a new study suggests.

The pill lowers ovarian cancer risk, even for smokers

January 18, 2018
(HealthDay)—It's known that use of the birth control pill is tied to lower odds for ovarian cancer, but new research shows the benefit extends to smokers or women who are obese.

Researchers develop swallowable test to detect pre-cancerous Barrett's esophagus

January 17, 2018
Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett's esophagus that offers promise ...

Scientists zoom in to watch DNA code being read

January 17, 2018
Scientists have unveiled incredible images of how the DNA code is read and interpreted—revealing new detail about one of the fundamental processes of life.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.